Robert Califf’s return to the top job at the FDA is in peril, reports Politico. But another news source predicts the Senate will eventually vote in favor of making him the FDA commissioner for a second time.
The Biden’s administration tortuous journey to having a permanent FDA commissioner continues to have twist and turns.
The administration waited nearly 10 months before settling on Robert Califf, M.D., as a nominee in November. Politico reported today that “Califf’s supporters fear his candidacy is on the brink” and that the White is House is asking Anthony Fauci and other advisers to help “rescue the nomination.”
“If the vote was held today, he would not have the vote,” Politico quoted an unnamed source as saying.
‘White House isn’t supporting him’: Biden’s FDA pick left in limbo,” was the headline on the story, which is, however, largely based on unnamed sources.
A Bloomberg Law story posted on Monday cast Califf’s chances in a more optimistic light. Echoing statements made when Califf was nominated in November, the Bloomberg Law story says that Califf’s “previous stint as FDA chief will help him secure the role once again despite growing lawmaker opposition over this drug company ties.”
Politico reported that five Democrats — Sens. Bernie Sanders (I-Vt.), Joe Manchin (D-W.Va.), Ed Markey (D-Mass.), Maggie Hassan (D-N.H.) and Richard Blumenthal (D-Conn.) — have signaled opposition to Califf’s nomination.
The Senate Health, Education, Labor, and Pensions Committee voted 13-8 in favor of Califf’s nomination two weeks ago. Sanders and Hassan voted against forwarding his name.
Califf has been criticized by Democrats for his ties to the pharmaceutical industry, which have included consulting fees and other financial arrangements. His supporters tend to speak of his experience and expertise in clinical trials.
Califf, a cardiologist, was FDA commissioner from Feb. 2016 through Jan. 2017.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
Black Women Can Successfully Be Started on Long-Acting Apretude for HIV PrEP | IAS 2025
July 14th 2025Increasing the use of Apretude among Black women requires not only expanding awareness of the long-acting PrEP regimen in various clinics but also providing more flexible scheduling and partnering with specialty pharmacies.
Read More